Secukinumab - Novartis
Alternative Names: AIN-457; Anti-interleukin 17A monoclonal antibody; Cosentyx; KB-03303A; Kosentikusu; NVP-AIN-457; ScaphoLatest Information Update: 06 Feb 2024
At a glance
- Originator Alcon; Novartis
- Developer Beth Israel Deaconess Medical Center; GWT-TUD GmbH; Icahn School of Medicine at Mount Sinai; Novartis
- Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action IL17A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ankylosing spondylitis; Hidradenitis suppurativa; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
- Registered Juvenile rheumatoid arthritis
- Phase III Giant cell arteritis; Graves ophthalmopathy; Polymyalgia rheumatica; Rotator cuff injuries
- Phase II Atopic dermatitis; Discoid lupus erythematosus; Necrobiosis lipoidica; SARS-CoV-2 acute respiratory disease; Tendon injuries
- Discontinued Alopecia areata; Asthma; Crohn's disease; Dry eyes; Lichen planus; Lupus nephritis; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus; Uveitis
Most Recent Events
- 06 Feb 2024 Novartis plans to file a regulatory submission for Polymyalgia rheumatica in 2026 (Novartis pipeline, February 2024)
- 31 Dec 2023 Discontinued - Phase-III for Lupus nephritis (Adjunctive treatment) in Spain, Australia, Brazil, Colombia, Philippines, Portugal, Slovakia, Thailand, Czech Republic, Guatemala, Japan, South Korea, Vietnam (SC)
- 31 Dec 2023 Discontinued - Phase-III for Lupus nephritis (Combination therapy) in Germany, United Kingdom, Greece, USA, Peru, Australia, Brazil, Brazil, China, Colombia, Croatia, Czech Republic, Denmark, France, France, Guatemala, India, India, Italy, Japan, South Korea, Latvia, Mexico, Norway, Portugal, Philippines, Romania, Russia, Slovakia, Slovakia, South Africa, Spain, Spain, Sweden, Sweden, Switzerland, Taiwan, Thailand, Turkey, Vietnam, Chile (SC)